Wolverine Stack
BPC-157 + TB-500 · Wolverine blend · BPC/TB stack
Named research blend of BPC-157 plus TB-500 — the default two-peptide healing stack. We already have a full guide and GLOW/KLOW (which add GHK-Cu ± KPV). This leaf is the blend SKU itself. Each component is research-only; BPC-157 is FDA Category 2. No combined clinical trial.
Mechanism of Action
Wolverine is BPC-157 + TB-500 in one named stack. BPC-157 is a 15-aa gastric peptide with extensive animal repair literature and no Phase 3. TB-500 is a thymosin β-4 fragment studied for actin/cell migration. GLOW adds GHK-Cu; KLOW adds KPV. There is no combined RCT.
Source: PMID: 29936067 (BPC-157), PMID: 20435714 (Tβ4/TB-500); see also /blog/wolverine-stack-peptide-guide
Dosing Protocol
| Typical Dose | BPC-157 250-500 mcg/day · TB-500 2-5 mg twice weekly |
| Frequency | Daily (BPC-157) · 2× weekly (TB-500) |
| Half-Life | Minutes (BPC IV PK) / ~2 hours (TB-500 metabolites longer) |
| Common Vial Sizes | 10 mg |
Dosing Protocols
Component-wise (not a single INN)
Administration
Expected Timeline
Who Is It For?
Recovery stack
LowTwo research peptides. BPC-157 is FDA Category 2. This is a name, not a drug.
Reconstitution Example
Safety & Considerations
Research blend. Angiogenic theoretical risk in active cancer. Sterile technique. See the Wolverine guide for reconstitution walkthroughs.
Regulatory & Legal Status
BPC-157 is FDA Category 2. TB-500 is research-only. Combination is not an approved product
Competitive athletes subject to anti-doping controls should not use Wolverine Stack.
Research Chemical
US Compounding: Not eligible / not available
⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.
Wolverine Stack vs. GLOW Stack
| Attribute | Wolverine Stack | GLOW Stack |
|---|---|---|
| Components | BPC-157 + TB-500 | GHK-Cu + BPC-157 + TB-500 |
| Job | Two-peptide recovery | Recovery plus copper-peptide skin/ECM |
| Evidence | Component preclinical; no blend RCT | Same — community blend |
| PIP | Usually milder (no GHK-Cu) | GHK-Cu sting is the rate limiter |
Verdict: Wolverine is the two-peptide core. GLOW adds GHK-Cu. KLOW adds KPV on top of GLOW. Ingredient count is not evidence quality.
Dosing Quick Reference
Frequently Asked Questions
Wolverine vs GLOW vs KLOW?▼
Can I mix both in one syringe?▼
References
- Sikiric et al. “BPC-157 reviews.” Various (2018). PMID: 29936067
- Goldstein / Tβ4 literature “Thymosin beta-4 / TB-500 actin literature.” Various (2010). PMID: 20435714
📚 Related Articles
Looking for a trusted source? See our recommended suppliers →
Independently tested · COA-verified · Save 10% with our exclusive code